Biosensia is a Point-of-Care in-vitro diagnostics company that has a novel point-of-care platform, RapiPlex, available for licensing.
RapiPlex combines highly innovative technologies to produce a practical, rapid, multiplexing POC in-vitro diagnostics (IVD) platform, enabling access to a broad range of diagnostic applications.
Its component chip and cartridge system are compatible with a variety of common biological sample types, including whole blood, serum, saliva, urine and nasal/genital swabs.
Funding Rounds (2) - $4.5MUpdate
Atlantic Bridge is a private equity firm with offices in Dublin and London, focusing on Middle...
Seroba Kernel Life Sciences Limited (Seroba Kernel) is a European life science venture capital...
Enterprise Ireland is the government agency responsible for the development and promotion of the...
Street Capital Financial Corporation is a Canadian wholesale lending company. As a wholesale...
Belfield Innovation Park